EcoDrugPlus

P2x Purinoceptor 4-Like

Ensembl ID : ENSCVAG00000002499
Gene Symbol: LOC107104991
3 Cross references
195 Possible Orthologues:

P2y Purinoceptor 12-Like

Ensembl ID : ENSCVAG00000005299
Gene Symbol: LOC107081907
3 Cross references
182 Possible Orthologues:

Pim-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCVAG00000004867
Gene Symbol: PIM1
3 Cross references
250 Possible Orthologues:

Pim-3 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCVAG00000003098
Gene Symbol: PIM3
3 Cross references
196 Possible Orthologues:

Rac-Beta Serine/threonine-Protein Kinase

Ensembl ID : ENSCVAG00000018905
Gene Symbol: LOC107083482
3 Cross references
199 Possible Orthologues:

Rac-Gamma Serine/threonine-Protein Kinase

Ensembl ID : ENSCVAG00000016822
Gene Symbol: LOC107099926
3 Cross references
203 Possible Orthologues:

Rela Proto-Oncogene, Nf-Kb Subunit

Ensembl ID : ENSCVAG00000023334
Gene Symbol: RELA
3 Cross references
201 Possible Orthologues:

Raf-1 Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSCVAG00000012816
Gene Symbol: RAF1
3 Cross references
207 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 1

Ensembl ID : ENSCVAG00000020717
Gene Symbol: ROCK1
3 Cross references
210 Possible Orthologues:

Rho Associated Coiled-Coil Containing Protein Kinase 2

Ensembl ID : ENSCVAG00000022919
Gene Symbol: ROCK2
3 Cross references
216 Possible Orthologues:

Sem1 26s Proteasome Complex Subunit

Ensembl ID : ENSCVAG00000015390
Gene Symbol: SEM1
3 Cross references
156 Possible Orthologues:

Src Proto-Oncogene, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCVAG00000000334
Gene Symbol: SRC
4 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).